Thomas Hodgkin
I found something interesting while I was on ebay the other day. Someone in the United States is selling an original printing of Thomas Hodgkin's doctoral thesis. Entitled Dissertatio Physiologica Inauguralis De ABSORBENDI FUNCTIONE (in Latin), it was printed in Edinburgh in 1823. This should not be confused with his famous paper "On Some Morbid Appearances of the Absorbent Glands and Spleen" published in Medico-Chirurgical Transactions, the journal of the Medical and Chirurgical Society in London 9 years later.
I added the info to my original Hodgkin's Disease Timeline.
You might want to see the auction - it will probably end before you read this - it was up to $702.00 when I last saw it - a bit high for a hard working survivor.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
